Disproquima acquires Res Pharma to advance “life science industry innovation”
12 Jan 2024 --- Disproquima acquires Italian nutraceutical, cosmetic, pharmaceutical and food ingredients producer Res Pharma, a move the company says will significantly expand its portfolio and contribute to its innovation, sustainability and adaptability to current market trends.
Known for its extensive distribution network and a diverse range of raw materials and ingredients, Disproquima’s acquisition of Res Pharma is a testament to its commitment for the acquisition to not just be an expansion but also a fusion of complementary strengths and shared values.
“Res Pharma shares our commitment to excellence and innovation in the Life Science Industry,’ says Jordi Sánchez, Disproquima’s CEO. “This strategic move allows us to enhance our capabilities and further support our clients with a comprehensive suite of products and services.”
Expanding presence
Disproquima is well known for its many high-quality ingredients such as Rephyll, a Piper Nigrum β-caryophyllene and turmeric extract for pain management and Flavoxale, an immunity boosting and exclusive blend of propolis extract, Manuka honey and essential oil.
The company states that Res Pharma has 60 years experience in the industry and has been commended for its meticulous selection of premium ingredients and its holistic approach to providing focused solutions.
The company further highlights that integrating Res Pharma’s expertise into its operations will enhance its service offerings and bolster its quality and customer satisfaction within this constantly evolving and highly competitive market.
“This acquisition marks an exciting chapter for Res Pharma,” explains Letizia Facchini, president at Res Pharma. Joining forces with Disproquima opens up new opportunities for us to continue delivering exceptional value to our customers.”
Edited by William Bradford Nichols
